-
Mashup Score: 1Annamycin granted Orphan Drug Designation by the EMA - 21 day(s) ago
On April 18, 2024, the European Medicines Agency granted Orphan Drug Designation to annamycin, a next-generation anthracycline, for the treatment of patients with AML.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1BVX001 granted Orphan Drug Designation by the U.S. FDA - 25 day(s) ago
On April 17, 2024, the U.S. Food and Drug Administration granted Orphan Drug Designation to BVX001, a novel twin CD33/CD7 targeting bispecific antibody-drug conjugate, for the treatment of patients with acute myeloid leukemia.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Annamycin granted Orphan Drug Designation by the EMA - 25 day(s) ago
On April 18, 2024, the European Medicines Agency granted Orphan Drug Designation to annamycin, a next-generation anthracycline, for the treatment of patients with AML.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
Here, we summarize a multicenter retrospective study evaluating the efficacy and safety of ivosidenib in patients with IDH1-mutated R/R AML post-allo-HSCT.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Oral decitabine and cedazuridine + venetoclax for the treatment of older patients with newly diagnosed AML - 1 month(s) ago
Here, we summarize a phase II study investigating the efficacy and safety of the oral decitabine and cedazuridine + venetoclax for the treatment of patients aged β₯60 years with newly diagnosed AML or with relapsed/refractory AML.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7VALDAC: A prospective study of venetoclax and low-dose cytarabine for MRD and oligoblastic relapse in AML - 1 month(s) ago
Here, we summarize a prospective phase II study of venetoclax + low-dose cytarabine in patients with acute myeloid leukemia and either MRD or oligoblastic relapse.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 9Reduced-toxicity conditioning regimen for older patients with AML: fludarabine plus treosulfan - 1 month(s) ago
Here, we summarize an observational comparative analysis of fludarabine + treosulfan vs fludarabine + melphalan or busulfan + cyclophosphamide as a conditioning regimen for older patients with acute myeloid leukemia prior to allogeneic hematopoietic stem cell transplantation.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
Here, we summarize results from a phase I/II trial by Daver et al. investigating the safety and antileukemic activity of pivekimab sunirine in the treatment of relapsed/refractory acute myeloid leukemia.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet-
The safety and antileukemic activity of pivekimab sunirine is being investigated in an ongoing phase I/II trial for the treatment of relapsed/refractory AML. Read our summary of the latest data to learn moreπ: https://t.co/kGf5teLBFE #AMLsm #leusm #leukemia #MedicalEducation https://t.co/u15opgRkxH
-
-
Mashup Score: 9Priority Review of a new drug application for revumenib in the treatment of patients with R/R KMT2Ar AML and ALL - 2 month(s) ago
The FDA grants Priority Review for a New Drug Application for revumenib for the treatment of R/R KMT2Ar AML and ALL after positive results from the AUGMENT-101 trial.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5
Here, we summarize presentations from ASH 2023 by Russel.1, Othman.2,4, Loo.3, and Gui.5,6 discussing the prognostic utility of measurable residual disease in patients with AML.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
π¨ NEWS π¨ @EMA_News grants Orphan Drug Designation to annamycin, a next-generation anthracycline, for the treatment of patients with acute myeloid leukemia. Read more here: https://t.co/7GZ27k88dG #MedNews #leusm #AML